Baudax Bio, Inc. (BXRX) SEC Filing 8-K Material Event for the period ending Wednesday, February 9, 2022

Baudax Bio, Inc.

CIK: 1780097 Ticker: BXRX

View differences made from one to another to evaluate Baudax Bio, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Baudax Bio, Inc..


Assess how Baudax Bio, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Baudax Bio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: BXRX
CIK: 1780097
Form Type: 8-K Corporate News
Accession Number: 0000950170-22-001032
Submitted to the SEC: Thu Feb 10 2022 7:01:05 AM EST
Accepted by the SEC: Thu Feb 10 2022
Period: Wednesday, February 9, 2022
Industry: Health And Allied
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: